Navigation Links
PLC Systems Defers Pivotal Study of RenalGuard(TM) in the U.S.
Date:7/21/2008

o start the trial with our targeted study sites. We remain very confident that RenalGuard is a highly promising therapy addressing an unmet market need and are optimistic that the results from the CCM study will provide critical validation for our technology.

"In addition, beyond our focus on the CIN market in 2009, with a CE Mark in hand we plan to focus on several new applications for RenalGuard in the European Union (EU) capitalizing on the automated fluid balancing capabilities of our system. Specifically, there are several medical applications, such as cisplatin chemotherapy, where inducing high urine flow rates is beneficial for patients and is a standard of care. High urine flow rates are also frequently seen in post kidney transplant patients, where the careful monitoring and replacement of fluid losses helps avoid the risk of damage to the transplanted kidney. Accurate and timely matching of replacement fluids is important in these instances in order to best preserve and/or optimize kidney function. RenalGuard provides an automated method of measuring urine outputs and then matching these outputs with replacement fluid inputs, eliminating to a large degree what is otherwise an intensive and time-consuming manual balancing task for physicians and nurses in these situations. We plan to aggressively investigate these new market opportunities for RenalGuard throughout the EU in the coming year as part of our broader EU launch."

About RenalGuard

RenalGuard is designed to reduce the potentially toxic effects that contrast media can have on the kidneys when it is administered to patients undergoing image-guided procedures, such as those performed when placing drug-eluting stents. It is believed that allowing contrast media to dwell in the kidneys can lead to CIN. By inducing and maintaining a high urine flow rate before, during and after these image-guided procedures, it is believed the incidence rates of CIN in at-risk patients can be reduced
'/>"/>

SOURCE PLC Systems Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
2. PLC Systems Announces Approval of First European Study to Evaluate RenalGuard(TM)
3. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
4. PLC Systems Reports Fourth Quarter 2007 Results
5. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
6. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
7. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
8. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
9. Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health
10. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
11. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of Centers ... 2015 enrollment data shows that 81 percent of seniors ... and extra discounts at certain pharmacies. The findings were ... pharmacy plans are now the foundation of Medicare Part ...
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... 14, 2011 Regulus Therapeutics Inc ., a ... medicines targeting microRNAs, today announced that it has added ... The addition of Dr. Hannon, a researcher whose work ... microRNA pathway, increases SAB membership to six pioneers in ...
... Renal Therapies Division of B. Braun Medical ... Plasmat™ Futura System for H.E.L.P. ®   LDL Apheresis ... therapy provides a more easy-to-use system for clinicians ... severe hypercholesterolemia. (Logo: http://photos.prnewswire.com/prnh/20081022/NYW008LOGO) ...
Cached Medicine Technology:Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 2Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 3Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 4Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 5B. Braun Renal Therapies Division Announces Availability of Advanced Apheresis Therapy System 2
(Date:1/22/2015)... (PRWEB) January 23, 2015 LunaDress, with its ... the fashion industry. Now, the business is showing its latest ... women’s dresses. , According to the company’s CEO, all the ... now offered with big discounts, up to 80% off. All ...
(Date:1/22/2015)... TN (PRWEB) January 22, 2015 Gabe’s Chemo Duck ... Duck App, the first app ever created for kids with cancer. ... Apple phones and devices, is filled with enjoyable games to help ... and treatments. The free app helps to keep kids entertained, educated ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... diseases, including Age-Related Macular Degeneration and Diabetic ... ... Charlesson, LLC ("Charlesson"),today announced that it is the recipient of several ... and an award from the Oklahoma Center for the Advancement of ...
... -- In the 25 years since establishing the Dyslexia ... Albert Galaburda, MD, has witnessed a dramatic transformation in ... Over the years, there have been a host of ... the Division of Behavioral Neurology at BIDMC whose work ...
... - Solaris Platform is Now Supported to Help ... Supporting growing,demand within the biomedical market for ... the availability of Release 1.3,of SLIM Search. The ... and sensitivity for biomedical research and development.,Version 1.3 ...
... Food for Kids with Diabetes" by Robyn Webb, ... a child with diabetes,doesn,t have to mean making ... http://www.clevelandclinicpress.org/ ), publishing arm of Cleveland,Clinic ( http://www.clevelandclinic.org/ ... for Kids with Diabetes" by award-winning nutritionist and,columnist ...
... (Nasdaq: IMCL ) and Bristol-Myers Squibb Company ... established an agreement with Merck KGaA for,the co-development ... terms of the agreement, ImClone Systems, Bristol-Myers,Squibb and ... to develop and,following regulatory approval, market ERBITUX in ...
... aureus Infections in the, United States, shows that hospital-caused MRSA infections are ... have,consistently understated the size of the problem and have failed to call ... from these ... infections., NEW YORK, Oct. ...
Cached Medicine News:Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 2Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 3Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 4Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 5Health News:BIDMC Dyslexia Research Lab celebrates 25th anniversary 2Health News:Release 1.3 of SLIM Search Now Available 2Health News:New Cleveland Clinic Press Healthy Cookbook Helps Diabetic Kids 2Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 2Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 3Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 4Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 5Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 6Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 7Health News:The Journal of the American Medical Association (JAMA) Article Reveals Scope of MRSA Infections 2
Bruns bone curette, 9, oval, solid actagonal handle....
MRI curette, 8.5" overall length....
15" overall length, 5" handle....
9.5" overall length, 4.5" handle....
Medicine Products: